Zhao, Wen-Ning http://orcid.org/0000-0002-5824-2032
Tobe, Brian T. D.
Udeshi, Namrata D. http://orcid.org/0000-0001-5312-1402
Xuan, Lucius L.
Pernia, Cameron D.
Zolg, Daniel P.
Roberts, Amanda J.
Mani, Deepak
Blumenthal, Sarah R.
Kurtser, Iren
Patnaik, Debasis http://orcid.org/0000-0002-9829-3352
Gaisina, Irina http://orcid.org/0000-0002-8668-3222
Bishop, Joshua
Sheridan, Steven D.
Lalonde, Jasmin http://orcid.org/0000-0002-6797-1894
Carr, Steven A.
Snyder, Evan Y.
Haggarty, Stephen J.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R33MH087896)
Article History
Received: 11 July 2019
Revised: 8 November 2019
Accepted: 21 November 2019
First Online: 24 February 2020
Conflict of interest
: S.J.H. is a member of the scientific advisory board of Psy Therapeutics, Frequency Therapeutics and Souvien Therapeutics, none of whom were involved in the present study. S.J.H. also has financial interest in Rodin Therapeutics and is an inventor on IP licensed to this entity that is unrelated to this study. S.J.H. has also received speaking or consulting fees from Amgen, Merck, Regenacy Pharmaceuticals, and AstraZeneca as well as sponsored research from AstraZeneca and JW Pharmaceuticals unrelated to the content of this paper. All other authors declare that they have no conflict of interest.